enGene Therapeutics Inc.

ENGN Nasdaq SEC CIK 1980845
Follow enGene Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$32.5M −12.1% vs same quarter last year
EPS, diluted −$0.47 +17.5% vs same quarter last year
Operating cash flow −$18.9M +26.1% vs same quarter last year
Operating income −$34M −13.6% vs same quarter last year
Net income by quarter
−$15.3M
−$25.8M
−$29M
−$37.9M
−$30.2M
−$32.5M
Q4 24 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$100.7M
FY24−$49.2M
FY23−$25.1M
FY22−$17.7M
FY21-